NASDAQ$KLRS
Kalaris Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023.
AlloVir reported its Q2 2023 financial results, highlighting the progress of its allogeneic, off-the-shelf virus-specific T cell (VST) programs, including posoleucel. The company's three Phase 3 global registrational trials for posoleucel are ongoing, with data expected in the second half of 2024. AlloVir's cash position is expected to fund operations into 2025, through anticipated data readouts from the posoleucel Phase 3 trials.
- Three Phase 3 global registrational trials of posoleucel continue to enroll, with data anticipated in the second half of 2024.
- Positive data from the Phase 2 trial of posoleucel for treatment of BK viremia in kidney transplant recipients was presented at the American Transplant Congress (ATC 2023).
- ALVR106 completed enrollment in the dose-escalation (Part A) portion of the Phase 1b/2a clinical trial.
- A recent stock offering extends cash runway through Phase 3 data readouts and into 2025.
Headline financials
Revenue & EPS history
Allovir · Revenue · Quarterly
$0
Forward guidance
For fiscal year 2023, AlloVir expects operating expenses to be in the range of $150 million to $170 million, excluding non-cash expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+0.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+5.9%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+33.6%
Q2 2022
Best reaction
-23.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -1.8% | +6.9% | +75.0% | |
| Q2 2025 | -10.9% | +0.4% | +56.2% | |
| Q2 2024 | -3.3% | -5.7% | +75.0% | |
| Q1 2025 | -6.1% | -2.8% | +5.6% | |
| Q4 2025 | -3.4% | +4.2% | -21.2% | |
| Q3 2024 | -23.8% | -23.0% | -37.8% | |
| Q1 2024 | -1.7% | -1.4% | +0.5% | |
| Q4 2023 | +0.7% | +2.5% | +5.5% | |
| Q3 2023 | +9.1% | +9.1% | +27.9% | |
| Q2 2023 | +3.0% | +0.3% | +6.6% | |
| Q1 2023 | +14.2% | +13.0% | +2.6% | |
| Q4 2022 | -6.1% | +5.5% | -30.9% | |
| Q3 2022 | +0.9% | +9.1% | +10.5% | |
| Q2 2022 | +33.6% | +37.7% | +31.7% | |
| Q1 2022 | +0.4% | -23.8% | -25.3% | |
| Q4 2021 | +2.3% | +3.6% | -14.1% | |
| Q3 2021 | -2.3% | -3.0% | -28.9% | |
| Q2 2021 | +6.1% | +0.6% | +0.0% | |
| Q1 2021 | +9.7% | +5.0% | +6.0% | |
| Q4 2020 | +0.5% | -2.5% | -29.4% | |
| Q3 2020 | -0.5% | -6.3% | +24.2% | |
| Q2 2020 | -9.7% | -20.6% | -9.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro